Evaluation of the efficacy, safety and glycaemic effects of evolocumab ( AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Aim: To examine the lipid and glycaemic effects of 52 weeks of treatment with evolocumab. Materials and M ethods: The D urable E ffect of PCSK9 A ntibody C ompared with P lacebo S tudy ( DESCARTES ) was a 52‐week placebo‐controlled trial of evolocumab that randomized 905 patients from 88 study centres in 9 countries, with 901 receiving at least one dose of study drug. For this post‐hoc analysis, DESCARTES patients were categorized by baseline glycaemic status: type 2 diabetes, impaired fasting glucose ( IFG ), metabolic syndrome ( MetS ) or none of these. Monthly subcutaneous evolocumab (420 mg) or placebo was administered. The main outcomes measured were percentage change in LDL ‐cholesterol ( LDL‐C ) at week 52 and safety. Results: A total of 413 patients had dysglycaemia (120, type 2 diabetes; 293, IFG ), 289 had MetS (194 also had IFG ) and 393 had none of these conditions. At week 52, evolocumab reduced LDL‐C by >50% in all subgroups, with favourable effects on other lipids. No significant differences in fasting plasma glucose, HbA1c , insulin, C ‐peptide or HOMA indices were seen in any subgroup between evolocumab and placebo at week 52. The overall incidence of new‐onset diabetes mellitus did not differ between placebo (6.6%) and evolocumab (5.6%); in those with baseline normoglycaemia, the incidences were 1.9% and 2.7%, respectively. Incidences of AEs were similar in evolocumab‐ and placebo‐treated patients. Conclusions: Evolocumab showed encouraging safety and efficacy at 52 weeks in patients with or without dysglycaemia or MetS . Changes in glycaemic parameters did not differ between evolocumab‐ and placebo‐treated patients within the glycaemic subgroups examined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Self-citationGenetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902604 · Cited by 1,671 · cited 1×
“Mendelian randomisation studies show the Lp(a) is an independent risk factor for atherosclerosis, although there is as yet no cardiovascular outcome evidence for Lp(a) lowering with drug therapy (33-35).”
BackgroundStroes, E. S., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., Roden, M., Stein, E., Tokgözoğlu, L., Nordestgaard, B. G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv043 · Cited by 1,443
Preiss, D. (2011) · JAMA · doi:10.1001/jama.2011.860 · Cited by 1,390
Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
Kamstrup, P. R. (2009) · JAMA · doi:10.1001/jama.2009.801 · Cited by 1,357 · cited 1×
“Mendelian randomisation studies show the Lp(a) is an independent risk factor for atherosclerosis, although there is as yet no cardiovascular outcome evidence for Lp(a) lowering with drug therapy (33-35).”
BackgroundPeters, S. A. E., Huxley, R. R., & Woodward, M. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60040-4 · Cited by 805
Cited by
Sabatine, M. S., Leiter, L. A., Wiviott, S. D., Giugliano, R. P., Deedwania, P., De Ferrari, G. M., Murphy, S. A., Kuder, J. F., Gouni-Berthold, I., Lewis, B. S., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30313-3 · Cited by 603
Da Dalt, L., Ruscica, M., Bonacina, F., Balzarotti, G., Dhyani, A., Di Cairano, E., Baragetti, A., Arnaboldi, L., De Metrio, S., Pellegatta, F., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy357 · Cited by 209
Insight into the Evolving Role of PCSK9
Maligłówka, M., Kosowski, M., Hachuła, M., Cyrnek, M., Bułdak, Ł., Basiak, M., Bołdys, A., Machnik, G., Bułdak, R. J., & Okopień, B. (2022) · Metabolites · doi:10.3390/metabo12030256 · Cited by 41
Metadata
- Authors
- Blom, D. J., Koren, M. J., Roth, E., Monsalvo, M. L., Djedjos, C. S., Nelson, P., Elliott, M., Wasserman, S. M., Ballantyne, C. M., & Holman, R. R.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2016-10-14
- Volume
- 19
- Issue
- 1
- Pages
- 98-107
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2522643247
- Cited by
- 64
- References
- 19
- FWCI
- 11.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of the efficacy, safety and glycaemic effects of evolocumab ( AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome. https://app.cochat.ai/papers/10.1111/dom.12788
- The paper
- Blom, D. J., Koren, M. J., Roth, E., Monsalvo, M. L., Djedjos, C. S., Nelson, P., Elliott, M., Wasserman, S. M., Ballantyne, C. M., & Holman, R. R. (2017). Evaluation of the efficacy, safety and glycaemic effects of evolocumab ( AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12788
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.